Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pneumococcal resistance in the UK

C E Goldsmith1, J E Moore, P G Murphy

  • 1Bacteriology Department and Northern Ireland Public Health Laboratory, Belfast City Hospital, UK.

The Journal of Antimicrobial Chemotherapy
|March 4, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meningococcal Disease in Northern Ireland - Past, Present & Future: MeningoNI Forum.

The Ulster medical journal·2018
Same author

Meningococcal Disease Section 1: Microbiology And Historical Perspective: MeningoNI Forum.

The Ulster medical journal·2018
Same author

Meningococcal Disease Section 2: Epidemiology and Vaccination of Meningococcal Disease in Northern Ireland: MeningoNI Forum.

The Ulster medical journal·2018
Same author

Meningococcal Disease Section 3: Diagnosis and Management: MeningoNI Forum.

The Ulster medical journal·2018
Same author

Meningococcal Disease Section 4: Post Disease Complications, Charity Support and Future Perspectives: MeningoNI Forum.

The Ulster medical journal·2018
Same author

Occurrence of Pseudomonas aeruginosa in waters: implications for patients with cystic fibrosis (CF).

Letters in applied microbiology·2018
Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026
Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026
Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Penicillin-resistant pneumococci (PRP) and multidrug-resistant pneumococci are increasing in the UK. This rise necessitates new treatments for pneumococcal infections, with grepafloxacin showing potential.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Penicillin-resistant pneumococci (PRP) and multidrug-resistant pneumococci (MDRP) first reported in 1967 and 1977, respectively.
  • These resistant strains have become a global health concern, with high prevalence rates reported in parts of Europe.
  • The UK was previously considered to have low PRP prevalence, but recent data indicate a significant increase.

Purpose of the Study:

  • To document the rising prevalence of PRP and MDRP in the UK.
  • To analyze trends in penicillin and erythromycin resistance in pneumococcal strains.
  • To assess cross-resistance patterns in PRP and evaluate potential new therapeutic agents.

Main Methods:

  • Examination of 3171 pneumococcal strains at the Northern Ireland Public Health Laboratory (NIPHL) between 1988 and 1995 using the oxacillin screening test.

Related Experiment Videos

  • Analysis of national surveillance data on PRP isolations reported to the Central Public Health Laboratory (CPHL).
  • Comparison of the in vitro activity of grepafloxacin against PRP with other quinolones and macrolides.

    • Main Results:

    • Penicillin resistance in pneumococci at NIPHL increased from <1% to 10.6% between 1988 and 1995.
    • The proportion of PRP with high-level resistance (>1 mg/L) rose from 0% to 36% during the same period.
    • Cross-resistance to cephalosporins (89%) and ciprofloxacin (78%) was high among PRP strains. National data showed a 2.5-fold increase in PRP prevalence between 1990 and 1995.

    Conclusions:

    • Both PRP and MDRP are demonstrably increasing in prevalence across the UK, with current trends suggesting an exponential growth phase.
    • The rising resistance rates have significant implications for the effective treatment of pneumococcal infections in the UK.
    • New anti-pneumococcal agents, such as the quinolone grepafloxacin, are needed and show promise for treating resistant strains.